Oncimmune Holdings PLC Key appointments to further strengthen management
23 September 2019 - 4:01PM
RNS Non-Regulatory
TIDMONC
Oncimmune Holdings PLC
23 September 2019
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Oncimmune makes key appointments to further strengthen
management teams
September 23(rd) , 2019 - Oncimmune Holdings plc (AIM: ONC.L), a
leading global immunodiagnostics group, today announces the
appointment of Professor Tariq Sethi as Chief Scientific Officer,
Matthew Luttrell as Chief Commercial Officer and Cléa Rosenfeld as
Head of Investor Relations.
Professor Tariq Sethi is a researcher, clinician and
entrepreneur with over 35 years of combined academic and industry
experience in the field of immunology, inflammation and Lung
Cancer. Prior to joining Oncimmune, Tariq was Chief Physician
Scientist, Vice President in the Clinical Discovery Unit
AstraZeneca and Emeritus Professor of Respiratory Medicine King's
College London, having previously been Vice President in
AstraZeneca's Respiratory Immunology Autoimmunity Translational
Medicine Unit and formally Professor of Respiratory Medicine and
Lung Cancer at Edinburgh University. He is also founder of Galecto
Biotech. His research interests focus on chronic inflammatory
diseases and fibrosis and the interaction between inflammation and
lung cancer. Given his skillset and experience Tariq is very well
placed to direct and lead Oncimmune's discovery research,
translational and clinical programmes effectively. Tariq joins
Oncimmune as from 1 October 2019 as its Chief Scientific Officer,
and will also become part of the Senior Leadership Team.
Matthew Luttrell is a seasoned health and life science
commercial executive with experience gained in large pharmaceutical
companies across HIV, Rare Diseases, Oncology and Haematology.
After starting his career in the pharmaceutical sector in 2002 with
Eli Lilly, Matthew has held senior roles in Novo Nordisk, Gilead,
GlaxoSmithKline, Shire and, most recently, Takeda. Prior to joining
Oncimmune as Chief Commercial Officer, Matthew was Head of
Haematology, Growth and Emerging Markets at Shire (now Takeda).
Matthew's extensive experience leading direct and indirect sales
and implementing commercial strategy will enhance our commercial
sales capabilities as we seek to accelerate sales of our Early CDT
products. Matthew holds a bachelor's degree in Biomedical Science,
a master's degree in Marketing Management as well as a master's
degree in Business Administration. Matthew also joins the Senior
Leadership Team at Oncimmune as from 1 October 2019.
Cléa Rosenfeld joined the Oncimmune team as Head of Investor
Relations in July 2019. Cléa is a senior investor relations and
corporate communications professional with over 15 years of
experience working in FTSE 100 and 250 companies with global
businesses and international shareholder bases. Cléa was Head of
Investor Relations at Shire Plc for 11 years, where she helped
bring the company from a FTSE 250 Company to a top 50 FTSE company.
Her significant experience within the investor relations community
and her ability to develop and execute corporate strategy makes her
a valuable addition to our team.
Dr Adam M Hill, Chief Executive Officer of Oncimmune
commented:
"The appointments of Tariq, Matthew and Cléa add yet more
expertise and depth to our leadership teams as we establish
Oncimmune as a key player in supporting critical clinical decisions
across the cancer care pathway. I'm delighted to welcome them and
am pleased that Oncimmune's potential attracts such high quality,
experienced and seasoned professionals.
"The delivery of Oncimmune's three-year forward strategy
continues to progress at speed with the achievement of important
milestones this year. The results of the landmark Scottish ECLS
trial using our EarlyCDT(R) Lung test was presented at the World
Conference for Lung Cancer on 9(th) September 2019. The trial
further validated the use of Oncimmune's platform technology as a
screening modality, identifying cancer four years or more before
standard clinical diagnosis. Our strategy is one of Partnership by
Design and transactions with Biodesix in the US and R-Pharm in
Russia further demonstrate the commercial potential of Oncimmune's
technology platform."
-Ends-
For further information:
Oncimmune Holdings plc
Cléa Rosenfeld, Head of Investor Relations
Clea.rosenfeld@oncimmune.com
Media enquiries:
FTI Consulting
Brett Pollard, Andrew Ward
+44 (0) 20 3727 1000
Oncimmune@fticonsulting.com
About Oncimmune
Beating cancer, one test at a time
The battle against cancer hinges on early detection and then the
delivery of effective treatment. Oncimmune is working to
revolutionise both the detection of cancer and its treatment by
harnessing the sophisticated disease detecting capabilities of the
immune system to find cancer in its early stages. Our diagnostic
tests assist clinicians to identify the presence of cancer four
years or more before standard clinical diagnosis, whilst our
technology platform and sample biobanks are helping healthcare
companies to develop new cancer treatments.
Oncimmune was founded in 2002 and launched its platform
technology in 2009, followed by its first commercial tests,
EarlyCDT Lung and EarlyCDT Liver. To date, over 155,000 tests have
been performed for patients worldwide. EarlyCDT Lung was also used
in what is believed to be the largest randomised controlled study
for the early detection of lung cancer using biomarkers, the
National Health Service (NHS) ECLS study of 12,209 high-risk
smokers in Scotland. The study met its primary endpoint - showing
that the use of EarlyCDT Lung with subsequent X-ray and
computerised tomography (CT) scan reduced the incidence of patients
with late-stage lung cancer or unclassified presentation at
diagnosis, compared to standard clinical practice.
Oncimmune, headquartered at its laboratory facility in
Nottingham, UK, has a discovery research centre in Dortmund,
Germany and a CLIA lab in Kansas, US as well as offices in London,
UK and a representative office in Shanghai, China. Oncimmune joined
the Alternative Investment Market (AIM) of the London Stock
Exchange in May 2016 under the ticker ONC.L.
What is EarlyCDT Lung?
A blood test using a panel of seven immunogenic proteins for the
testing of tumour-related antibodies specific to lung cancer.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEAKNAADNNEFF
(END) Dow Jones Newswires
September 23, 2019 02:01 ET (06:01 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024